Interview with Philippe Baudier, Managing Director, S.M.B. Laboratories
Mr Baudier, what inspired you when you joined the company back in 1978 and what are your main goals today? Prior to joining SMB Laboratories, I worked in a publishing…
Address: 26-28, rue de la Pastorale1080 – Brussels – Belgium
Tel: +32.2.411.48.28
S.M.B. is a Belgian based pharmaceutical company with global ambitions. Its objective is to become a leading European player in the field of oral and pulmonary drug delivery systems by being an innovative actor in the pharmaceutical industry.
Thanks to the success of its R&D Department, S.M.B. has become internationally recognized in the field of human health care in various high-tech areas such as Micropellets (microgranules for once daily administration), Lidose® (semi-solid lipidic matrix in hard capsule formulation), Divule® (high gloss gelatine coated tabs), DPI (Dry Powder Inhaler) and Effervescent Tablets design and large scale production.
Together with its exclusive partners, S.M.B. Technology S.A. (Contract Manufacturing) and GALEPHAR M/F (Contract R&D), Laboratoires SMB’s activity embraces a large spectrum of competences in initial R&D, continuous R&D, Clinical Trials, Analytics, production, Regulatory Affairs and Marketing, supporting a pipeline of in-house formulations.
S.M.B. proposes a balanced portfolio of products mainly in:
Respiratory tract
Cardiovascular system
Pain management
OTC
Mr Baudier, what inspired you when you joined the company back in 1978 and what are your main goals today? Prior to joining SMB Laboratories, I worked in a publishing…
Vanja Hoeben oversees the Benelux cluster for South Africa-headquartered specialty and branded pharma firm Aspen. He describes the reorganisation that his organisation has undergone in the past few years, some…
Maria Fernanda Prado highlights some of the lessons drawn from her extensive experience in emerging markets which remain applicable in her current role as Janssen’s managing director for the Benelux…
Japanese-headquartered Takeda has been undergoing a transformation in recent years, becoming the global leader in rare diseases with the acquisition of Shire in 2018 and divesting ‘non-core’ assets in OTC…
Werner De Prins oversees Bayer’s operations in Benelux, a significant region for the global group with over 2000 employees, a turnover of around EUR 1.2 billion and 10 different sites…
Stefan Joris of the Belgian Cystic Fibrosis Association (BCFA) highlights the progress that has been made on cystic fibrosis screening of newborns and reimbursement of innovative modulator therapies in Belgium…
Dr Frank Nobels, one of Belgium’s leading endocrinologists and diabetologists, introduces the Belgian Diabetes Forum – a multi-stakeholder initiative which aims to create efficient policy engagement in diabetes and make…
With two in-house Clinical Research Units (PCRUs), Pfizer uniquely keeps its phase I research within the company. As Medical/Scientific advisor at the Brussels PCRU and with a history of more…
After almost 20 years with AbbVie, Renaud Decroix still feels as engaged and motivated as ever by the goal of having a remarkable impact on patients’ lives. Decroix highlights some…
Medaxes – the Belgian industry association for companies producing generic and biosimilar medicines, as well as other off-patent medicines and self-care products – welcomed a new CEO in 2022, Jasmien…
Théa veteran and GM of the French ophthalmology midcap’s BeLux affiliate, Ivan Perrichon, reveals the company’s plans to pursue its growth trajectory, launch ten new products in Belgium and reach…
Belgium is a hugely significant country for GSK – which employs 9,000 people in the country – as host to three of the firm’s major vaccine sites, the global headquarters…
Paul Newton of Vertex Pharmaceuticals – one of the first biotech firms to use an explicit strategy of rational drug design rather than combinatorial chemistry – outlines the company’s footprint…
See our Cookie Privacy Policy Here
